1st Mover in Scalable Biomanufacturing in Space

LEO Biosciences is establishing the orbital capabilities for healthcare applications to advance treatments for cancer, cardiovascular disease and neurodegenerative disorders.

Explore OSPRI → Partner with us

ISS Flight Validation — Launching 2027

ISS National LabCurrent awardee, Lab-to-LEO platform

2027First ISS validation flight

2020Founded

100+ yearsCombined spaceflight heritage

Who we are

Hardware and know-how to grow, process and study living cells in space

Our flagship platform, the Orbital Science Platform for Research & Innovation — OSPRI, is an automated, closed-system bioprocessing system for the International Space Station and commercial free-flyers.

OSPRI supports research and biomanufacturing with organoids, stem cells, cardiac tissue, extracellular vesicles and more. Founded in 2020 by a team with decades of spaceflight life-sciences experience, LEO Biosciences works with research and industry partners to turn microgravity into a practical setting for medicine and manufacturing.

Spaceflight, a unique environment

Unlocking bottlenecks in bioprocessing, and new market applications

Microgravity+Radiation=Novel cellular behavior

Enhanced 3D growthCells self-assemble into tissue-like structures without scaffolds or settling.

Altered proliferationGrowth rates shift in ways that can be studied and put to use.

Changes in viabilityCell survival responds to the orbital environment.

Changes in potencyFunction and output of cell products can change in orbit.

Applications for research in space

Three high-value paths from orbit to the clinic

Biomanufacturing

Stem cells, organoids and engineered tissue

Scalable production of shear-sensitive cell products in a closed, automated system.

See applications → Disease modeling

Cancer, cardiovascular and neurological disease

Microgravity-enabled models of disease progression, immune dysfunction and sarcopenia.

See applications → Regenerative medicine

Drug development and personalized medicine

Insight into aging and countermeasures, with a path to cell and cell-free therapies.

See applications →

The OSPRI platform

A validated, microgravity-optimized platform for in-space cell biomanufacturing, engineered to scale

Proven terrestrial bioprocessing technology, re-engineered for microgravity. Multi-phase fluid flow, aeration and radiation shielding are designed in from the start.

See the platform →

Platform snapshot

Automated, closed-system bioprocessing

From cryovial thaw to culture, analysis and sealed sample return — designed for the ISS and commercial free-flyers.

Fly your cells with us on the 2027 ISS validation flights

This work is supported by the International Space Station U.S. National Laboratory · Join us in shaping the future of medicine from space.